BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Circulating tumor cells (CTCs) are an independent prognostic factor in metastatic breast cancer. The aim of this study was to assess the prognostic value of baseline CTCs in metastatic IBC patients. PATIENTS AND METHODS: This retrospective study included 42 metastatic IBC and 107 metastatic non-IBC patients treated with first- or second-line chemotherapy from January 2004 to December 2007 at MD Anderson Cancer Center. CTCs were detected and enumerated before patients started chemotherapy using the CellSearch system. RESULTS: Ten (23.8%) IBC patients versus 48 (44.9%) non-IBC patients had baseline CTCs > or =5 per 7.5 ml of peripheral blood. IBC patients had a lower mean +/- SEM CTCs than non-IBC patients (7.6 +/- 2.9 versus 34.2 +/- 9.1; P = 0.02). The estimated median overall survival was 26.5 versus 18.3 months (P = 0.68) in IBC patients and 37.4 versus 18.3 months (P = 0.016) in non-IBC patients with CTCs <5 and CTCs > or =5, respectively. CONCLUSIONS: Metastatic IBC patients had a lower prevalence and fewer CTCs in comparison to metastatic non-IBC patients. Survival of metastatic IBC patients with <5 CTCs was not significantly better than that of patients with > or =5 CTCs. Further research is warranted with prospective assessment of CTCs in IBC patients and their biological characterization.
BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Circulating tumor cells (CTCs) are an independent prognostic factor in metastatic breast cancer. The aim of this study was to assess the prognostic value of baseline CTCs in metastatic IBC patients. PATIENTS AND METHODS: This retrospective study included 42 metastatic IBC and 107 metastatic non-IBC patients treated with first- or second-line chemotherapy from January 2004 to December 2007 at MD Anderson Cancer Center. CTCs were detected and enumerated before patients started chemotherapy using the CellSearch system. RESULTS: Ten (23.8%) IBC patients versus 48 (44.9%) non-IBC patients had baseline CTCs > or =5 per 7.5 ml of peripheral blood. IBC patients had a lower mean +/- SEM CTCs than non-IBC patients (7.6 +/- 2.9 versus 34.2 +/- 9.1; P = 0.02). The estimated median overall survival was 26.5 versus 18.3 months (P = 0.68) in IBC patients and 37.4 versus 18.3 months (P = 0.016) in non-IBC patients with CTCs <5 and CTCs > or =5, respectively. CONCLUSIONS: Metastatic IBC patients had a lower prevalence and fewer CTCs in comparison to metastatic non-IBC patients. Survival of metastatic IBC patients with <5 CTCs was not significantly better than that of patients with > or =5 CTCs. Further research is warranted with prospective assessment of CTCs in IBC patients and their biological characterization.
Authors: Astrid Blom; Shailender Bhatia; Stephanie Pietromonaco; Karen Koehler; Jayasri G Iyer; Kotaro Nagase; Kelly Paulson; Daniel E Sabath; Paul Nghiem Journal: J Am Acad Dermatol Date: 2013-12-31 Impact factor: 11.527
Authors: Carolyn S Hall; Mandar Karhade; Barbara A Laubacher; Henry M Kuerer; Savitri Krishnamurthy; Sarah DeSnyder; Amber E Anderson; Vicente Valero; Naoto T Ueno; Yisheng Li; Xiao Su; Anthony Lucci Journal: J Natl Cancer Inst Date: 2015-09-14 Impact factor: 13.506
Authors: Michal Mego; Antonio Giordano; Ugo De Giorgi; Hiroko Masuda; Limin Hsu; Mario Giuliano; Tamer M Fouad; Shaheenah Dawood; Naoto T Ueno; Vicente Valero; Eleni Andreopoulou; Ricardo H Alvarez; Wendy A Woodward; Gabriel N Hortobagyi; Massimo Cristofanilli; James M Reuben Journal: Breast Cancer Res Date: 2015-01-09 Impact factor: 6.466
Authors: M Mego; H Gao; E N Cohen; S Anfossi; A Giordano; T Sanda; T M Fouad; U De Giorgi; M Giuliano; W A Woodward; R H Alvarez; V Valero; N T Ueno; G N Hortobagyi; M Cristofanilli; J M Reuben Journal: J Cancer Date: 2016-06-03 Impact factor: 4.207
Authors: Wendy A Woodward; Massimo Cristofanilli; Sofia D Merajver; Steven Van Laere; Lajos Pusztai; Francois Bertucci; Fedor Berditchevski; Kornelia Polyak; Beth Overmoyer; Gayathri R Devi; Esta Sterneck; Robert Schneider; Bisrat G Debeb; Xiaoping Wang; Kenneth L van Golen; Randa El-Zein; Omar M Rahal; Angela Alexander; James M Reuben; Savitri Krishnamurthy; Anthony Lucci; Naoto T Ueno Journal: J Cancer Date: 2017-10-09 Impact factor: 4.207